References
- Pharmacyclics, LLC [Internet]. Imbruvica product monograph. 2017. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44
- Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129:2581–2584.
- Beyer A, Ganti B, Majkrzak A, et al. A perfect storm: tyrosine kinase inhibitor-associated polymorphic ventricular tachycardia. J Emerg Med. 2017;52:e123–e127.
- Tomcsányi J, Nényei Z, Mátrai Z, et al. Ibrutinib, an approved tyrosine kinase inhibitor as a potential cause of recurrent polymorphic ventricular tachycardia. JACC Clin Electrophysiol. 2016;2:847–849.
- Wallace N, Wong E, Cooper D, et al. A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma. Clin Case Rep. 2016;4:1120–1121.
- World Health Organization (WHO) [Internet]. The use of the WHO-UMC system for standardised case causality assessment. 2005. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf
- National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) [Internet]. Health Topics: Arrhythmia risk factors. 2018. Available from: https://www.nhlbi.nih.gov/health-topics/arrhythmia
- Zipes DP, Camm J, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the ACC/AHA Task Force and the ESC for practice guidelines. J Am Coll Cardiol. 2006;48:e247–e346.
- Chugh SS, Reinier K, Teodorescu C, et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis. 2008;51:213–228.
- Koplan BA, Stevenson WG. Ventricular tachycardia and sudden cardiac death. Mayo Clin Proc. 2009;84:289–297.
- Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA. 2007;104:13283–13288.
- McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829–3830.